Pharmacotherapy for squamous-cell carcinoma of the head and neck

被引：11
|
作者：
Papaspyrou, Giorgos [2 ]
Werner, Jochen A. [2 ]
Dietz, Andreas [1 ]
机构：
[1] Dept Otolaryngol Head & Neck Surg, D-04103 Leipzig, Germany
[2] Univ Marburg, Dept Otolaryngol Head & Neck Surg, D-35037 Marburg, Germany
来源：
EXPERT OPINION ON PHARMACOTHERAPY | 2011年 / 12卷 / 03期
关键词：
GROWTH-FACTOR RECEPTOR; PHASE-II TRIAL; TYROSINE KINASE INHIBITOR; RECURRENT HEAD; METASTATIC/RECURRENT HEAD; ANTIBODY CETUXIMAB; PLUS CETUXIMAB; SINGLE-AGENT; CISPLATIN; CANCER;
D O I：
10.1517/14656566.2011.523698
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Areas covered: The purpose of this review is to provide an update on the pharmacotherapy for the treatment of HNSCC focusing mainly on molecular-targeted therapies. An overview of the different novel therapeutic agents that can selectively inhibit signaling pathways and receptors that are involved in the development and progression of cancer especially in HNSCC is presented. Expert opinion: The treatment of HNSCC is traditionally based on surgery and radiotherapy for early-stage HNSCC; however, chemotherapy is no longer used only for palliation, and individualized patient treatment assisted by molecular-targeted therapies represents a future therapeutic challenge.
引用
收藏
页码：397 / 409
页数：13
相关论文
共 50 条
  • [1] Pharmacotherapy of head and neck squamous cell carcinoma
    Pan, Quintin
    Gorin, Michael A.
    Teknos, Theodoros N.
    EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (14) : 2291 - 2302
  • [2] Targeted treatment of head and neck squamous-cell carcinoma: potential of lapatinib
    Gandhi, Mitul D.
    Agulnik, Mark
    ONCOTARGETS AND THERAPY, 2014, 7 : 245 - 251
  • [3] Targeted Therapies in Squamous Cell Carcinoma of the Head and Neck
    Gold, Kathryn A.
    Lee, Ho-Young
    Kim, Edward S.
    CANCER, 2009, 115 (05) : 922 - 935
  • [4] The mutational spectrum of squamous-cell carcinoma of the head and neck: targetable genetic events and clinical impact
    Mountzios, G.
    Rampias, T.
    Psyrri, A.
    ANNALS OF ONCOLOGY, 2014, 25 (10) : 1889 - 1900
  • [5] Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck
    Osorio Rodriguez, Marta
    Cruz Rivero, Teresa
    del Castillo Bahi, Ramon
    Roca Muchuli, Carlos
    Azcue Bilbao, Miguel
    Neninger Vinageras, Elia
    Alert, Jose
    Jimenez Galainena, Julio
    Rodriguez, Edmundo
    Gracias, Elias
    Mulen, Barbara
    Wilkinson, Barbara
    Lucia de Armas, Esther
    Perez, Kirenia
    Pineda, Idael
    Frometa, Milagros
    Leonard, Idrissa
    Mullens, Vladimir
    Viada, Carmen
    Luaces, Patricia
    Torres, Olga
    Iznaga, Normando
    Crombet, Tania
    CANCER BIOLOGY & THERAPY, 2010, 9 (05) : 343 - 349
  • [6] Systemic Treatment for Squamous Cell Carcinoma of the Head and Neck
    Shetty, Aditya V.
    Wong, Deborah J.
    OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA, 2017, 50 (04) : 775 - +
  • [7] Phase II trial of cisplatin and Gemcitabine in advanced squamous-cell carcinoma of the head and neck
    Hitt, R
    Castellano, D
    Hidalgo, M
    García-Carbonero, R
    Peña, M
    Brandariz, A
    Millán, JM
    Vincent, JJA
    Cortés-Funes, H
    ANNALS OF ONCOLOGY, 1998, 9 (12) : 1347 - 1349
  • [8] Immunotherapy for Head and Neck Squamous Cell Carcinoma
    Schoppy, David W.
    Sunwoo, John B.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2015, 29 (06) : 1033 - +
  • [9] Anti-EGFR Therapy: Strategies in Head and Neck Squamous Cell Carcinoma
    Oliveira-Silva, Renato J.
    de Carvalho, Ana Carolina
    Viana, Luciano de Souza
    Carvalho, Andre L.
    Reis, Rui M.
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2016, 11 (02) : 170 - 183
  • [10] Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma
    Cassell, Andre
    Grandis, Jennifer R.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2010, 19 (06) : 709 - 722
12345